





Value-Based Care in Oncology: Collaborating to Optimize Patient Outcomes



Panel

Adam S. Kittai, MD
Hematology/Oncology



Victoria Nachar, PharmD, BCOP

Former Hematology Clinical Pharmacist Specialist
University of Michigan Rogel Cancer Center



Jay Weaver, PharmD, MPH

Former Chief Pharmacy Officer
Blue Cross Blue Shield of Kansas City



This content is for informational purposes only. The views expressed herein belong to the participants and do not necessarily reflect those of BeOne Medicines, formerly known as BeiGene or its affiliates. Panelists have been compensated by BeOne for their participation in the development of this content.

Background

Value-based care is frequently viewed from a population health perspective. Our panel discussed how value-based care in oncology must evolve to better address the needs of patients and how outcomes can be optimized through communication and collaboration.

Key Highlights

- 1 Standard approaches and metrics assessing value-based care **have not always considered the impact to the patient**
- 2 Patients should be **engaged in shared decision-making**; the care team should have **transparent discussions** with them about the **value of the care they are receiving**
- 3 Clinical trials in oncology need to evolve to **include endpoints such as patient-reported outcomes**
- 4 Optimizing ways of communicating with patients is **essential to achieving value-based care** and helping support them throughout their treatment journey
- 5 Investment in ancillary services and support—patient navigators, clinical pharmacists, social workers—**increases value irrespective of payment models**

“If we have a subgroup of patients who aren’t achieving the same outcomes as other groups of patients, that’s something that we need to look at because we need to provide value to everyone.”

— Adam S. Kittai, MD

Strategic Framework for Implementing Value-Based Care to Achieve Better Patient Outcomes¹

Better Patient Outcomes



Adapted from Teisberg E et al. *Acad Med.* 2020;95(5):683.

“[I]t needs to start with the way clinical trials are designed in terms of what outcomes are most important and looking at outcomes that matter to patients.”

— Victoria Nachar, PharmD, BCOP

Reference: 1. Teisberg E, Wallace S, O’Hara S. Defining and implementing value-based health care: a strategic framework. *Acad Med.* 2020;95(5):682-685.

Additional Resources

Booth CM, Sengar M, Goodman A, et al. Common sense oncology: outcomes that matter. *Lancet Oncol.* 2023;24(8):833-835.

Hwang TJ, Gyawali B. Association between progression-free survival and patients’ quality of life in cancer clinical trials. *Int J Cancer.* 2019;144(7):1746-1751.

Lewis C, Horstman C, Blumenthal D, et al. Value-based care: what it is, and why it’s needed. *Commonwealth Fund.* February 7, 2023. <https://doi.org/10.26099/fw31-3463>

Mooghali M, Mitchell AP, Skydel JJ, Ross JS, Wallach JD, Ramachandran R. Characterization of accelerated approval status, trial endpoints and results, and recommendations in guidelines for oncology drug treatments from the National Comprehensive Cancer Network: cross-sectional study. *BMJ Med.* 2024;3(1):e000802.

Visit BeOneEngage.com for additional information and resources.



Scan with your smartphone camera to visit the site



BeOne Medicines is a trademark owned by BeOne Medicines I GmbH or its affiliates.
© BeOne Medicines I GmbH, 2026 All Rights Reserved.
0824-NP-PRC-003 January 2026